CA3037154A1 - Protein biomarkers for diseases associated with the contact activation system - Google Patents

Protein biomarkers for diseases associated with the contact activation system Download PDF

Info

Publication number
CA3037154A1
CA3037154A1 CA3037154A CA3037154A CA3037154A1 CA 3037154 A1 CA3037154 A1 CA 3037154A1 CA 3037154 A CA3037154 A CA 3037154A CA 3037154 A CA3037154 A CA 3037154A CA 3037154 A1 CA3037154 A1 CA 3037154A1
Authority
CA
Canada
Prior art keywords
protein
biomarker
subject
hae
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3037154A
Other languages
English (en)
French (fr)
Inventor
Daniel J. Sexton
Malini VISWANATHAN
Ryan Faucette
Tripti GAUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA3037154A1 publication Critical patent/CA3037154A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3037154A 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system Pending CA3037154A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662395712P 2016-09-16 2016-09-16
US62/395,712 2016-09-16
US201762518492P 2017-06-12 2017-06-12
US62/518,492 2017-06-12
PCT/US2017/051749 WO2018053244A1 (en) 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system

Publications (1)

Publication Number Publication Date
CA3037154A1 true CA3037154A1 (en) 2018-03-22

Family

ID=59974881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3037154A Pending CA3037154A1 (en) 2016-09-16 2017-09-15 Protein biomarkers for diseases associated with the contact activation system

Country Status (13)

Country Link
US (2) US11815516B2 (cg-RX-API-DMAC7.html)
EP (1) EP3513196A1 (cg-RX-API-DMAC7.html)
JP (4) JP7225089B2 (cg-RX-API-DMAC7.html)
KR (3) KR102806918B1 (cg-RX-API-DMAC7.html)
CN (2) CN109716138B (cg-RX-API-DMAC7.html)
AU (2) AU2017325983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005179A2 (cg-RX-API-DMAC7.html)
CA (1) CA3037154A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019002599A2 (cg-RX-API-DMAC7.html)
IL (2) IL265195B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019002932A (cg-RX-API-DMAC7.html)
NZ (1) NZ792394A (cg-RX-API-DMAC7.html)
WO (1) WO2018053244A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
CN113092769A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液补体c4-a及其多肽片段在过敏性疾病中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001174463A (ja) 1999-12-17 2001-06-29 Hsp Research Institute Inc 自己免疫疾患又は腫瘍の診断方法
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
JP4399593B2 (ja) * 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
CA2630838A1 (en) 2005-11-23 2007-05-31 Georg Dewald Detection and treatment of drug associated angioedema
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20090104605A1 (en) * 2006-12-14 2009-04-23 Gary Siuzdak Diagnosis of sepsis
AU2009285585A1 (en) * 2008-08-28 2010-03-04 Wyeth Llc Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases
US8883153B2 (en) 2009-03-27 2014-11-11 The Research for The State University of New York Methods for preventing and treating angioedema
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
US9102942B2 (en) 2010-02-04 2015-08-11 EWHA University—Industry Collaboration Foundation Pharmaceutical composition for inhibiting abnormal proliferation of cells
JP2011226882A (ja) * 2010-04-19 2011-11-10 Kitasato Institute 泌尿器系疾患マーカー及びその抗体、並びに泌尿器系疾患診断用キット
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
US20130102486A1 (en) * 2011-10-20 2013-04-25 The Board Of Trustees Of The Leland Stanford Junior University Perp as a prognostic and diagnostic marker for dysplasia and cancer
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
JP6656926B2 (ja) * 2013-01-20 2020-03-04 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
AU2014340450B2 (en) * 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) * 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) * 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
CA2940585C (en) * 2014-04-15 2023-08-08 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Differential diagnosis of eczema and psoriasis
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
IL315175A (en) 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema

Also Published As

Publication number Publication date
US20240142468A1 (en) 2024-05-02
US11815516B2 (en) 2023-11-14
KR20250073510A (ko) 2025-05-27
JP2025124852A (ja) 2025-08-26
IL265195B1 (en) 2024-10-01
BR112019005179A2 (pt) 2019-07-02
JP7412616B2 (ja) 2024-01-12
CN109716138A (zh) 2019-05-03
KR20230044024A (ko) 2023-03-31
MX2019002932A (es) 2019-07-15
CN109716138B (zh) 2023-10-03
JP7693788B2 (ja) 2025-06-17
IL265195A (en) 2019-05-30
WO2018053244A1 (en) 2018-03-22
JP7225089B2 (ja) 2023-02-20
JP2019529906A (ja) 2019-10-17
JP2024023904A (ja) 2024-02-21
AU2017325983A1 (en) 2019-03-21
NZ751193A (en) 2024-02-23
KR102513485B1 (ko) 2023-03-23
NZ792394A (en) 2025-07-25
EP3513196A1 (en) 2019-07-24
JP2023058608A (ja) 2023-04-25
AU2024201506A1 (en) 2024-03-28
CO2019002599A2 (es) 2019-03-29
US20210285962A1 (en) 2021-09-16
IL265195B2 (en) 2025-02-01
KR102806918B1 (ko) 2025-05-14
IL315799A (en) 2024-11-01
AU2024201506B2 (en) 2025-12-18
AU2017325983B2 (en) 2023-12-07
CN117192130A (zh) 2023-12-08
MX2024009782A (es) 2024-08-19
KR20190053913A (ko) 2019-05-20

Similar Documents

Publication Publication Date Title
US12188948B2 (en) Metabolite biomarkers for diseases associated with the contact activation system
US20240142468A1 (en) Protein biomarkers for diseases associated with the contact activation system
EP4548103A2 (en) Protein biomarkers for lanadelumab treatment
EA045712B1 (ru) Белковые биомаркеры заболеваний, ассоциированных с контактной системой активации
NZ792393A (en) Metabolite biomarkers for diseases associated with the contact activation system

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220823

EEER Examination request

Effective date: 20220823

EEER Examination request

Effective date: 20220823

EEER Examination request

Effective date: 20220823